Novartis' Cosentyx Leads CHMP Extensions, Inductos Suspended
This article was originally published in Scrip
Executive Summary
The EU's CHMP has given the go-ahead for expanding the approved indications for Novartis's first-in-class of interleukin-17A (IL-17A) inhibitor Cosentyx (secukinumab) to encompass psoriatic arthritis and ankylosing spondylitis.